AstraZeneca Pharma India Gets Approval to Import and Sell Sodium Zirconium Cyclosilicate for Hyperkalaemia Treatment

New Delhi (The Uttam Hindu): AstraZeneca Pharma India Ltd announced on Thursday that it has received approval from India's drug regulator to import and sell sodium zirconium cyclosilicate powder for oral suspension, which is used to treat hyperkalaemia (higher-than-normal potassium levels in the blood) in adults.

The approval was granted by the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India. The company has been authorized to import the 5 g and 10 g formulations of sodium zirconium cyclosilicate powder for oral suspension, branded as Lokelma.

Sodium zirconium cyclosilicate is indicated for managing hyperkalaemia in adult patients. With this regulatory approval, AstraZeneca Pharma India is now set to launch Lokelma in India, subject to receiving other related statutory approvals.

The company’s new product aims to provide a significant treatment option for patients with hyperkalaemia, contributing to the ongoing efforts to address this condition in India.